389 related articles for article (PubMed ID: 25100159)
1. Modelling the impact of improving screening and treatment of chronic hepatitis C virus infection on future hepatocellular carcinoma rates and liver-related mortality.
Cramp ME; Rosenberg WM; Ryder SD; Blach S; Parkes J
BMC Gastroenterol; 2014 Aug; 14():137. PubMed ID: 25100159
[TBL] [Abstract][Full Text] [Related]
2. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia.
Sievert W; Razavi H; Estes C; Thompson AJ; Zekry A; Roberts SK; Dore GJ
J Gastroenterol Hepatol; 2014 Aug; 29 Suppl 1():1-9. PubMed ID: 25055928
[TBL] [Abstract][Full Text] [Related]
3. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
[TBL] [Abstract][Full Text] [Related]
4. Epidemiology and natural history of hepatitis C virus infection among children and young people.
Modin L; Arshad A; Wilkes B; Benselin J; Lloyd C; Irving WL; Kelly DA
J Hepatol; 2019 Mar; 70(3):371-378. PubMed ID: 30496763
[TBL] [Abstract][Full Text] [Related]
5. Increased uptake and new therapies are needed to avert rising hepatitis C-related end stage liver disease in England: modelling the predicted impact of treatment under different scenarios.
Harris RJ; Thomas B; Griffiths J; Costella A; Chapman R; Ramsay M; De Angelis D; Harris HE
J Hepatol; 2014 Sep; 61(3):530-7. PubMed ID: 24824282
[TBL] [Abstract][Full Text] [Related]
6. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
[TBL] [Abstract][Full Text] [Related]
7. Disease burden of chronic hepatitis C in Brazil.
Ferreira PR; Brandão-Mello CE; Estes C; Gonçales Júnior FL; Coelho HS; Razavi H; Cheinquer H; Wolff FH; Ferraz ML; Pessoa MG; Mendes-Correa MC
Braz J Infect Dis; 2015; 19(4):363-8. PubMed ID: 26051505
[TBL] [Abstract][Full Text] [Related]
8. Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin.
Moon C; Jung KS; Kim DY; Baatarkhuu O; Park JY; Kim BK; Kim SU; Ahn SH; Han KH
Dig Dis Sci; 2015 Feb; 60(2):573-81. PubMed ID: 25236421
[TBL] [Abstract][Full Text] [Related]
9. Treatment of hepatitis C virus leads to economic gains related to reduction in cases of hepatocellular carcinoma and decompensated cirrhosis in Japan.
Younossi ZM; Tanaka A; Eguchi Y; Henry L; Beckerman R; Mizokami M
J Viral Hepat; 2018 Aug; 25(8):945-951. PubMed ID: 29478258
[TBL] [Abstract][Full Text] [Related]
10. Estimating the impact of early hepatitis C virus clearance on hepatocellular carcinoma risk.
Darvishian M; Janjua NZ; Chong M; Cook D; Samji H; Butt ZA; Yu A; Alvarez M; Yoshida E; Ramji A; Wong J; Woods R; Tyndall M; Krajden M
J Viral Hepat; 2018 Dec; 25(12):1481-1492. PubMed ID: 30047609
[TBL] [Abstract][Full Text] [Related]
11. Forecasting the disease burden of chronic hepatitis C virus in Poland.
Flisiak R; Halota W; Tomasiewicz K; Kostrzewska K; Razavi HA; Gower EE
Eur J Gastroenterol Hepatol; 2015 Jan; 27(1):70-6. PubMed ID: 25426979
[TBL] [Abstract][Full Text] [Related]
12. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies.
Duberg AS; Blach S; Falconer K; Kåberg M; Razavi H; Aleman S
Scand J Gastroenterol; 2015 Feb; 50(2):233-44. PubMed ID: 25515032
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity.
Krassenburg LAP; Maan R; Ramji A; Manns MP; Cornberg M; Wedemeyer H; de Knegt RJ; Hansen BE; Janssen HLA; de Man RA; Feld JJ; van der Meer AJ
J Hepatol; 2021 May; 74(5):1053-1063. PubMed ID: 33242501
[TBL] [Abstract][Full Text] [Related]
14. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication.
van der Meer AJ; Feld JJ; Hofer H; Almasio PL; Calvaruso V; Fernández-Rodríguez CM; Aleman S; Ganne-Carrié N; D'Ambrosio R; Pol S; Trapero-Marugan M; Maan R; Moreno-Otero R; Mallet V; Hultcrantz R; Weiland O; Rutter K; Di Marco V; Alonso S; Bruno S; Colombo M; de Knegt RJ; Veldt BJ; Hansen BE; Janssen HLA
J Hepatol; 2017 Mar; 66(3):485-493. PubMed ID: 27780714
[TBL] [Abstract][Full Text] [Related]
15. Chronic hepatitis C in the Czech Republic: Forecasting the disease burden.
Fraňková S; Urbánek P; Husa P; Němeček V; Razavi H; Razavi-Shearer D; Chlíbek R; Šperl J
Cent Eur J Public Health; 2019 Jun; 27(2):93-98. PubMed ID: 31241282
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C and hepatitis B-related mortality in Spain.
García-Fulgueiras A; García-Pina R; Morant C; García-Ortuzar V; Génova R; Alvarez E
Eur J Gastroenterol Hepatol; 2009 Aug; 21(8):895-901. PubMed ID: 19357523
[TBL] [Abstract][Full Text] [Related]
17. Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVES.
Butt AA; Yan P; Bonilla H; Abou-Samra AB; Shaikh OS; Simon TG; Chung RT; Rogal SS;
Hepatology; 2015 Aug; 62(2):365-74. PubMed ID: 25847403
[TBL] [Abstract][Full Text] [Related]
18. Risk of hepatitis C virus related hepatocellular carcinoma between subjects with spontaneous and treatment-induced viral clearance.
Huang CF; Yeh ML; Huang CI; Lin YJ; Tsai PC; Lin ZY; Chan SY; Chen SC; Yang HI; Huang JF; Lu SN; Dai CY; Jen CL; Yuan Y; L'Italien G; Wang LY; Lee MH; Yu ML; Chuang WL; Chen CJ
Oncotarget; 2017 Jul; 8(27):43925-43933. PubMed ID: 28159934
[TBL] [Abstract][Full Text] [Related]
19. [Strategies for the prevention of hepatocellular carcinoma in the context of chronic viral hepatitis].
Schott E; Bergk A; Berg T
Z Gastroenterol; 2008 Jan; 46(1):69-80. PubMed ID: 18188819
[TBL] [Abstract][Full Text] [Related]
20. Impact of All-Oral Direct-Acting Antivirals on Clinical and Economic Outcomes in Patients With Chronic Hepatitis C in the United States.
Park H; Wang W; Henry L; Nelson DR
Hepatology; 2019 Mar; 69(3):1032-1045. PubMed ID: 30289989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
